Upon binding of their ligands, TLR7/8 and TLR9 recruit a cytoplasmic adaptor MyD88 and IRAKs, downstream of which the signaling pathways are divided to induce either inflammatory cytokines or type I IFNs.
|20237413||Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance||J. Clin. Invest.||2010|
|15276183||MD-2: the Toll 'gatekeeper' in endotoxin signalling||Trends Biochem Sci||2004|
|18652679||Comparison of human B cell activation by TLR7 and TLR9 agonists||BMC Immunol.||2008|